Table 3.
Anti‐HCV activities of 7‐deazapurine nucleosides
| Compound | EC50 [μM] (replicon)a | CC50 [μM] (replicon) | Ref. |
|---|---|---|---|
| 7‐Deazapurine ribonucleosides | |||
| 9a | 0.02 (1B); 0.03 (2A) | >44 (1B); > 44 (2A) | 44 |
| 9c | 0.06 (1B); 0.14 (2A) | >44 (1B); > 44 (2A) | 44 |
| 11c | 0.07 (1B); 0.10 (2A) | >44 (1B); > 44 (2A) | 44 |
| 40a | 2 | >300 | 110 |
| 41a | 5.7 | 5.7 | 91 |
| 41b | 3 | <10 | 91 |
| 44c | 0.11 (1B); 0.06 (2A) | >44 (1B); >44 (2A) | 95 |
| 44e | 0.47 (1B); 0.34 (2A) | >44 (1B); >44 (2A) | 95 |
| 45c | 0.06 (1B); 0.24 (2A) | >44 (1B); >44 (2A) | 95 |
| 45d | 0.23 (1B); 0.40 (2A) | >44 (1B); >44 (2A) | 95 |
| 45e | 0.13 (1B); 0.80 (2A) | >44 (1B); >44 (2A) | 95 |
| 56 | 0.4 | >250 | 108 |
| 57 | 0.6 | >200 | 108 |
| 58 | 0.27 (1B); 0.97 (2A) | >44 (1B); >44 (2A) | 44 |
| 59 | 1 | 150 | 110 |
| Sugar‐modified 7‐deazapurine nucleosides | |||
| 17 | 1.8 | 4.5 | 48 |
| 60a (MK‐0608) | 0.3 | >100 | 111 |
| 60b | 0.07 | >100 | 116 |
| 60c | 0.13 | ∼50 | 116 |
| 60d | 0.24 | 40 | 116 |
| 60e | 0.37 (1A); 0.38 (1B) | 19.75 (1A); 26.27 (1B) | 46 |
| 60f | 0.09 | nd | 117 |
| 61 | >50 | >100 | 111 |
| 62 | 3 | >100 | 118 |
| 63a | >50 | ndb | 119 |
| 63b | >50 | nd | 119 |
| 64 | 1.9 | nd | 120 |
| 65 | >100 | nd | 120 |
| 66 | 1.8 | nd | 120 |
| 67 | 23.8 | nd | 121 |
| 68 | 33.8 | nd | 121 |
| 69a | 18 | >300 | 110 |
| 69b | 15 | >200 | 110 |
| 70a | 2.66; >10 | 1165; >10 | 48, 124 |
| 70b | 1.1 | 10.4 | 48 |
| 70c | 24 | nd | 117 |
| 70d | 35 | nd | 120 |
| 71 | 0.9 | >50 | 125 |
| 72a | 0.11 | nd | 126 |
a
if replicon is not mentioned, the genotype is not specified in the original article;
b
nd, not determined